Edition:
India

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

39.53USD
2:29am IST
Change (% chg)

$0.24 (+0.61%)
Prev Close
$39.29
Open
$39.35
Day's High
$39.98
Day's Low
$39.11
Volume
2,125,747
Avg. Vol
2,187,775
52-wk High
$45.86
52-wk Low
$29.44

Select another date:

Tue, Dec 12 2017

BRIEF-Mylan Says Teva Has Dismissed Its Pending Litigation Against Co

* MYLAN NV - ANNOUNCED THAT TEVA HAS DISMISSED ITS PENDING DISTRICT COURT LITIGATION AGAINST MYLAN

BRIEF-Mylan And Aspen Announce Launch Of Generic Busulfex Injection

* MYLAN AND ASPEN ANNOUNCE LAUNCH OF GENERIC BUSULFEX® INJECTION

FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, making it the second copycat cancer drug to be approved in the United States.

BRIEF-FDA Approves Mylan's Heparin Sodium Injection

* FDA APPROVAL OF HEPARIN SODIUM INJECTION CONTINUES TO DEMONSTRATE MYLAN'S DEEP EXPERTISE IN DEVELOPING COMPLEX PRODUCTS

FDA approves Mylan's biosimilar of Roche's breast cancer treatment

Dec 1 The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster breast cancer treatment Herceptin.

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

BRIEF-Mylan announces voluntary delisting from the Tel Aviv Stock Exchange (TASE)

* Mylan announces voluntary delisting from the Tel Aviv Stock Exchange (TASE)

BRIEF-Mylan launches generic Clolar for injection

* Mylan launches generic Clolar for injection Source text for Eikon: Further company coverage:

BRIEF-Biocon says Mylan resubmits Biosimilar Trastuzumab and Pegfilgrastim dosseirs with EMA‍​

* Says mylan resubmits Biosimilar Trastuzumab and Pegfilgrastim dosseirs with EMA‍​ Source text for Eikon: Further company coverage:

Select another date: